Drugs / PF-06687234
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03414788 | Dec 2020 → Feb 2022 | inflammatory bowel disease | Pfizer | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02711462 | Feb → Aug 2016 | — | Pfizer | Terminated | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03269695 | Dec 2017 → Jan 2021 | ulcerative colitis | Pfizer | Terminated | Missed primary Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-06687234 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02711462 ↗ |
| Modality | Protein / enzyme biologic | “novel, human, single-chain variable fragment cytokine fusion protein” PMID 41684726 ↗ Feb 2026 |
| Route | Intravenous | “PF-06687234 will be administered via the SC or the IV route and in either single dose or multiple doses” NCT02711462 ↗ |
| Route | Subcutaneous | “PF-06687234 will be administered via the SC or the IV route and in either single dose or multiple doses” NCT02711462 ↗ |